688136 Kexing Biopharm
- 16.71
- -0.51-2.96%
Kexing Biopharm News
Kexon Pharmaceuticals (688136): Continued improvement in profitability and achieved a breakthrough in sales in the EU market
Kexing Pharmaceuticals (688136) Third Quarterly Report Review: High growth in export sales continues to accelerate the overseas commercialization process
Kexing Pharmaceuticals (688136): Performance is in line with expectations, optimistic that Bai Zi will accelerate overseas delivery
Kexing Pharmaceuticals (688136): Profitability restoration is expected to continue to focus on the pace of releasing new biopharmaceuticals overseas
Kexing Pharmaceuticals (688136): A Scarce Emerging Market Overseas Platform Turns Losses into Profits in 2024Q1
Kexing Pharmaceuticals (688136) Comment: Issuing an Equity Incentive Plan to Ensure the Smooth Implementation of the “Internationalization” Strategy
Kexing Pharmaceuticals (688136): The main business performance of recombinant proteins is steady, and the value of the overseas commercialization platform accelerates the realization of value
Kexon Pharmaceuticals (688136): The pace of GMP factory inspections in many countries is in line with expectations, and the EU is more certain that Bai Zi will go overseas
Kexing Pharmaceuticals (688136) Company Brief Review Report: Domestic business is stable and waiting for breakthroughs in internationalization
Kexing Pharmaceuticals (688136): The overseas recombinant protein business is about to reap profits in 24Q1
Kexing Pharmaceuticals (688136): Reducing costs, increasing efficiency, and speeding up the restoration of profitability in 24Q1
Kexing Pharmaceuticals (688136): The platform value of listed companies that have been approved overseas one after another is expected to be fulfilled
Kexing Pharmaceuticals (688136) Comment: “Overseas commercialization” is steadily advancing, and the actual controller's proposal to “buy back” shows confidence
Kexing Pharmaceuticals (688136) Company Brief Review Report: Overseas business has entered a stage of leapfrog development, and performance is expected to reach an inflection point
Kexing Pharmaceutical (688136): Focus on emerging markets to create the best commercialization platform for high-quality biopharmaceuticals in China
Kexing Pharmaceutical (688136) In-depth Report: Focusing on Potential Emerging Markets, Scarce Overseas Commercialization Platforms Set Sail
Kexon Pharmaceutical (688136): The pressure on the profit side slowed in the first three quarters, and biopharmaceuticals began to go overseas
Kexing Pharmaceutical (688136): The main business of recombinant protein is steady, and the amount of biopharmaceuticals is about to be released overseas
Kexing Pharmaceutical (688136): Rich overseas commercialization experience helps China's new drugs go overseas and continue to invest in R&D to promote new drug projects
Kexing Pharmaceutical (688136): Overseas sales growth accelerates, COVID-19 oral drug SHEN26 enters clinical phase I
Analysis
Price Target
No Data
No Data